Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 13,300 shares, a decrease of 50.9% from the December 15th total of 27,100 shares. Currently, 2.4% of the shares of the stock are short sold. Based on an average daily volume of 652,600 shares, the days-to-cover ratio is presently 0.0 days.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Bluejay Diagnostics stock. Anson Funds Management LP boosted its holdings in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) by 359.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the period. Anson Funds Management LP owned approximately 1.93% of Bluejay Diagnostics worth $41,000 at the end of the most recent quarter. 18.47% of the stock is currently owned by institutional investors.
Bluejay Diagnostics Trading Down 2.9 %
BJDX traded down $0.11 on Tuesday, reaching $3.55. The company had a trading volume of 12,453 shares, compared to its average volume of 84,032. Bluejay Diagnostics has a one year low of $3.03 and a one year high of $419.64. The company has a market capitalization of $1.96 million, a P/E ratio of 0.00 and a beta of 0.48. The company has a fifty day moving average of $4.12 and a 200-day moving average of $11.01.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Articles
- Five stocks we like better than Bluejay Diagnostics
- What to Know About Investing in Penny Stocks
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What is a Special Dividend?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Stock Splits, Do They Really Impact Investors?
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.